Alexandria's Blueprint: How a Real Estate Pioneer Continues to Shape Biotech's Future

PASADENA, CA – January 05, 2026 – As Alexandria Real Estate Equities, Inc. (NYSE: ARE) celebrates its 32nd anniversary, it marks more than just a corporate milestone. It commemorates the creation of an entire commercial real estate category—life science real estate—that has become the physical backbone of modern medical innovation. Founded in a garage in 1994, Alexandria has evolved into the preeminent owner and developer of mission-critical laboratory and office space, demonstrating remarkable resilience and market leadership, particularly as the broader life science industry navigates a period of significant turbulence.

While the sector grapples with shifting funding priorities, capital market volatility, and regulatory hurdles, Alexandria is underscoring its stability. The company's strategy, centered on creating large-scale, collaborative "Megacampus™" ecosystems in top-tier innovation hubs, appears to be a powerful insulator against market pressures, allowing it to not only weather the storm but thrive within it.

A Beacon of Stability in a Turbulent Market

The current landscape for the life science industry is fraught with challenges. Venture capital funding, after a record-breaking surge, has normalized to pre-pandemic levels. NIH funding allocations to key clusters like Boston and the San Francisco Bay Area saw declines in fiscal year 2025. This capital squeeze has had a direct impact on real estate, creating what is now widely considered a tenant's market.

Nationally, the life sciences vacancy rate climbed to a staggering 24.7% in the third quarter of 2025, a dramatic increase driven by a wave of new construction meeting subdued demand. In core markets like Greater Boston and the San Francisco Bay Area, vacancy rates have soared even higher, hovering between 26% and 33%. Yet, Alexandria's portfolio tells a starkly different story.

As of September 30, 2025, occupancy across its Megacampus properties in Greater Boston, the San Francisco Bay Area, and San Diego stood at a robust 91%. This figure is not just strong in isolation; it represents an 18% premium over the struggling market average in those same clusters. The company's market dominance is further evidenced by its leasing activity. From the beginning of 2023 through the third quarter of 2025, Alexandria's leasing volume in these three core markets accounted for an astounding 105% of the aggregate square footage leased by its next five largest competitors combined. This outsized performance is anchored by an average tenant retention rate of over 80% for the past five years, a testament to the strategic value tenants place on its curated environments.

While other landlords compete with declining rents and generous concessions to fill empty space, Alexandria's differentiated platform—which combines high-quality facilities with operational excellence and deep tenant relationships—continues to capture the lion's share of demand from the industry's most innovative companies.

From Real Estate to Real Cures: Fostering Innovation

Alexandria's business model is built on the premise that the right environment can accelerate scientific discovery. The company's impact extends far beyond providing physical lab space; it actively fosters the collaborative ecosystems where breakthroughs happen. The results of this strategy are tangible: in 2025, an impressive 39% of the 44 novel therapies approved by the U.S. Food and Drug Administration were developed or commercialized by companies operating within Alexandria's properties.

A prime example of this mission-driven approach is the company's pioneering public-private partnership with the Foundation for the National Institutes of Health (FNIH). Alexandria has taken a leadership role in initiating and driving the Multi-Level Assessment & Phenotyping in Depression (MAP-D) program, a bold initiative aimed at revolutionizing the understanding and treatment of major depressive disorder.

Affecting over 21 million American adults annually and carrying an economic burden of more than $380 billion, depression remains one of the nation's most pressing health crises. The MAP-D program seeks to modernize clinical trials by identifying and validating biological markers—or biomarkers—for the disorder. This would allow for more precise diagnoses and personalized treatment strategies, moving beyond the current one-size-fits-all approach. With the program's design phase now complete, a seminal clinical study is targeted to launch in May 2026, coinciding with Mental Health Awareness Month, with Alexandria continuing to play a major leadership role.

This initiative exemplifies how the company leverages its platform and influence to tackle critical, unmet medical needs, reinforcing the idea that its campuses are not just collections of buildings, but engines of human health advancement.

A Vision for the Next Era of Discovery

As the life science industry continues to evolve, the challenges it faces—from drug pricing pressures to intensifying global competition—only underscore the need for a stable, domestic innovation infrastructure.

"As the cornerstone of U.S. innovation and societal progress, the life science industry is navigating a period of change," said Joel S. Marcus, Alexandria's executive chairman and founder, in a recent statement. He noted that while challenges exist, they also "reinforce the importance of sustained and robust domestic life science investment to maintain U.S. global leadership."

Thirty-two years after its founding, Alexandria's role appears more critical than ever. By providing the specialized, collaborative environments essential for modern research, the company has created a durable model that supports scientific progress in both booming and challenging times. As it looks ahead, its focus remains fixed on empowering the scientists and companies working to discover the cures for the more than 90% of diseases that still lack effective treatments.